U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O3
Molecular Weight 138.121
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALICYLIC ACID

SMILES

c1ccc(c(c1)C(=O)O)O

InChI

InChIKey=YGSDEFSMJLZEOE-UHFFFAOYSA-N
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Salicylic acid is obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics. Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic. Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
Cyanide-resistant alternative respiration is strictly correlated to intracellular peroxide levels in Acremonium chrysogenum.
2001 Apr
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants.
2001 Apr
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane.
2001 Apr
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR.
2001 Apr
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes.
2001 Apr
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
2001 Apr
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
2001 Apr 17
Hereditary palmoplantar keratoderma (four cases in three generations).
2001 Feb
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.
2001 Feb
Ethylene-dependent salicylic acid regulates an expanded cell death response to a plant pathogen.
2001 Feb
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells.
2001 Jan
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action.
2001 Jan
Guidelines for the management of cutaneous warts.
2001 Jan
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.
2001 Jan
Ion channel-forming alamethicin is a potent elicitor of volatile biosynthesis and tendril coiling. Cross talk between jasmonate and salicylate signaling in lima bean.
2001 Jan
Free and conjugated benzoic acid in tobacco plants and cell cultures. Induced accumulation upon elicitation of defense responses and role as salicylic acid precursors.
2001 Jan
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors.
2001 Jan 24
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers.
2001 Jan 5
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts.
2001 Jun 1
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens.
2001 Mar
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
Action of 2,3-butanedione monoxime on capacitance and electromotility of guinea-pig cochlear outer hair cells.
2001 Mar 15
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes.
2001 Mar 23
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.
2001 May
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen.
2001 May 11
Patents

Sample Use Guides

adults 18 years and older: apply one patch to affected area and leave in place for up to 8-12 hours; if pain lasts lasts after using the first patch, a second patch may be applied for up to another 8 to 12 hours; use only one patch at a time; do not use more than 2 patches per day; do not use for more 3 days in a row
Route of Administration: Topical
In vitro tests with fresh dermatomed (0.3 to 0.4 mm thick) female breast skin and one leg skin specimen were conducted in Bronaugh flow-through Teflon diffusion cells with three chemicals used to simulate chemical warfare agents: 14C-radiolabeled methyl salicylate (MES), ethyl parathion (PT), and malathion (MT), at three dose levels (2, 20, and 200 mM). Tests were conducted at a skin temperature of 29 degrees C using a brief 30-min exposure to the chemical and a 6.5-h receivor collection period. Rapid absorption of all three chemicals was observed, with MES absorbed about 10-fold faster than PT and MT. For MES, PT, and MT, respectively, there was 32%, 7%, and 12% absorption into the receivor solution at the low dose (2 mM), 17%, 2%, and 3% at the medium dose (20 mM), and 11%, 1%, and 1% at the high dose (200 mM) levels. Including the skin depot for MES, PT, and MT, respectively, there was 40%, 41%, and 21% (low dose), 26%, 16%, and 8% (medium dose), and 13%, 19%, and 10% (high does) absorption.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:14:17 UTC 2021
Edited
by admin
on Fri Jun 25 21:14:17 UTC 2021
Record UNII
O414PZ4LPZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SALICYLIC ACID
EP   GREEN BOOK   HSDB   INCI   JAN   MART.   MI   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
MESALAZINE IMPURITY H [EP]
Common Name English
SALICYLIC ACID [USP-RS]
Common Name English
LAMIVUDINE RELATED COMPOUND SALICYLIC ACID [USP]
Common Name English
2-HYDROXYBENZENECARBOXYLIC ACID
Systematic Name English
COMPOUND W
Brand Name English
SALICYLIC ACID [WHO-DD]
Common Name English
SALICYLIC ACID [JAN]
Common Name English
SALICYLIC ACID [VANDF]
Common Name English
SALICYLIC ACID [INCI]
Common Name English
DR. SCHOLL'S CALLUS REMOVERS
Brand Name English
SALICYLICUM ACIDUM
HPUS  
Common Name English
FEMA NO. 3985
Code English
SALICYLIC ACID [MART.]
Common Name English
SALICYLICUM ACIDUM [HPUS]
Common Name English
SALICYLIC ACID [GREEN BOOK]
Common Name English
SALICYLIC ACID [MI]
Common Name English
SALICYLIC ACID [HSDB]
Common Name English
SALICYLATE
Systematic Name English
NSC-180
Code English
2-HYDROXYBENZOIC ACID [FHFI]
Common Name English
LAMIVUDINE IMPURITY C [EP]
Common Name English
2-HYDROXYBENZOIC ACID
FHFI  
Systematic Name English
ACIDUM SALICYLICUM [WHO-IP LATIN]
Common Name English
SALICYLIC ACID RS [USP]
Common Name English
SULFASALAZINE IMPURITY H [EP]
Common Name English
SALICYLIC ACID [EP MONOGRAPH]
Common Name English
LAMIVUDINE IMPURITY, SALICYLIC ACID- [USP]
Common Name English
SALICYLIC ACID [WHO-IP]
Common Name English
SALICYLIC ACID [USP]
Common Name English
K-557
Code English
SALICYLIC ACID [EP]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 358.710
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 333.310
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
NCI_THESAURUS C52588
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.510
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QD01AE12
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 862.3830
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
EPA PESTICIDE CODE 76602
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.720
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QS01BC08
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ATC S01BC08
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.110
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
FDA ORPHAN DRUG 359211
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QM02AC99
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
JECFA EVALUATION 2-HYDROXYBENZOIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ATC D01AE12
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
Code System Code Type Description
RXCUI
9525
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
HSDB
672
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
FDA UNII
O414PZ4LPZ
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
PUBCHEM
338
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
RXCUI
9522
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
ALTERNATIVE
LACTMED
Salicylic Acid
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
EVMPD
SUB15180MIG
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
WIKIPEDIA
SALICYLIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
CAS
69-72-7
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
USP_CATALOG
1609002
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
200-712-3
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
MESH
D020156
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
IUPHAR
4306
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
DRUG CENTRAL
2416
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
MERCK INDEX
M9739
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61934
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SALICYLIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY Description: Colourless crystals, usually needle-like, or a white, crystalline powder; odourless. Solubility: Slightly soluble in water; soluble in 4 parts of ethanol (~750 g/l) TS and in 3 parts of ether R. Category: Keratolytic. Storage: Salicylic acid should be kept in a well-closed container. Definition: Salicylic acid contains not less than 99.0% and not more than 101.0% of C7H6O3, calculated with reference to the dried substance.
ChEMBL
CHEMBL424
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
DRUG BANK
DB00936
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
EPA CompTox
69-72-7
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Salicylic acid content for water extract of plant callus was 3.22+/-0.06 as expressed as mg/100 g of dry base of extract. For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
MINOR
URINE
Related Record Type Details
PARENT -> IMPURITY
IDENTIFIED AS IMPURITY C Limits: impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
IMPURITY -> PARENT
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
PARENT -> IMPURITY
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY